Statin Use and Incident Nuclear Cataract

Barbara E. K. Klein, MD, MPH
Ronald Klein, MD, MPH
Kristine E. Lee, MS
Lisa M. Grady, BS

S t o t i n s a r e w i d e l y u s e d t o
reduce serum cholesterol for
cardiovascular disease preven-
tion. Associations have been
claimed between statin use and a va-
riety of diseases, including Alzheimer
disease and multiple sclerosis. An
inverse association between age-
related macular degeneration and
statin use has been reported, although a similar relationship was
not found in a large, population-based
study. Statins have been shown to
have antioxidant activity, especially
in the context of cardiovascular
disease, where nitric oxide–derived
oxidant species that are active in
atherosclerosis have been shown to
be suppressed by statins. In addi-
tion, statins have been found in the
lens.

Oxidative stress has been postu-
lated as a risk factor for age-related cata-
ракt. Although there is much specu-
lation about the mechanism of increased oxidation in lenses that de-
velop cataract, some evidence, but not all, suggests an association be-
tween nutritional intake of antioxi-
dants and age-related cataract. Protec-
tive effects on the lens of specific antioxidant nutrients have been ad-
dressed by many studies. Furthermore, risk factors as well as
protective factors appear to differ be-
tween the types of cataract. Oxidative
stress is thought to be related in par-
ticular to nuclear cataract.

We sought to determine if statin use is as-
associated with reduced risk of age-
related cataract, and nuclear cataract specifically.

M E T H O D S

The population and recruitment meth-
ods for the full cohort of the Beaver Dam
Eye Study have been described in pre-
vious reports. In brief, at baseline, a pri-
ate census of the population of Beaver Dam, Wis, was performed
from September 15, 1987, to May 4, 1988,
to identify all residents in the city or
township of Beaver Dam who were 43 to
84 years of age. The tenets of the Decla-
rarion of Helsinki were followed, ten in-
fomed consent was obtained from each participant. Ninety-nine per-
cent of the population was non-
Hispanic white as classified by the ex-
aminer, who questioned participants
when uncertain. A total of 5924 eli-
gible individuals were identified and in-
vited for a baseline examination be-
 tween March 1, 1988, and September
14, 1990. The participants included

C O N T E X T  Statins are widely prescribed for their lipid-lowering effects but also have putative antioxidant properties. Oxidative stress is believed to play a role in the de-
velopment of nuclear cataract, but little is known regarding the relationship of statin use and cataract incidence.

O B J E C T I V E  To evaluate the relationship of use of statins and incident cataract in adults in a midwestern community in the United States.

D E S I G N , S E T T I N G , A N D P A R T I C I P A N T S  The Beaver Dam Eye Study, an observational, longitudinal, population-based study of age-related eye disease in Beaver Dam, Wis.

R E S U L T S  A total of 210 persons developed incident nuclear cataract in the interval from 1998-2000 to 2003-2005. Five-year incidence of nuclear cataract was 12.2% in

www.jama.com

©2006 American Medical Association. All rights reserved.
in this analysis are shown in FIGURE 1. Comparisons between participants and nonparticipants at baseline and follow-up have been presented elsewhere.30-32 In brief, nonparticipants (dead or alive) at previous examinations were older, had fewer years of education, were less likely to be currently employed, had poorer visual acuity, were more likely to have had cardiovascular disease and diabetes, smoked more, and had higher systolic blood pressure. The most common reason for nonparticipation was death.

Study visits have occurred at 5-year intervals since the baseline examination for 3 follow-up evaluations. All eligible individuals were invited for follow-up examinations, regardless of previous participation or disease status.

The analyses pertinent to this report are based on exposures measured in the 2962 persons seen at the third examination. Analyses are based on cataract present in the worse eye. Persons without gradable photographs in both eyes were excluded, as well as persons with prevalent cataract in either eye. Numbers for each cataract type are similar to those for nuclear cataract (FIGURE 2).

The same protocols, with few additions or deletions, were used at each examination phase. Photographs of the lens were taken after pharmacologic dilation. Slit-lamp photographs were taken to grade the degree of nuclear sclerosis. Retroillumination photographs were taken to grade presence and severity of cortical and posterior subcapsular cataracts. The protocols for photography and for the grading procedures have been previously described.39 Grading procedures for the lens photographs were based on detailed codified decision rules.39 Graders were masked to participant identity. Scores for nuclear sclerosis were based on comparisons with standard photographs, which resulted in a 5-step scale of severity based on opacity of the nucleus. Severities greater than standard 3 were considered nuclear cataract. Scores for cortical and posterior subcapsular cataracts were based on estimated amount of involvement.

Nonfasting blood specimens were obtained at the time of examination. An aliquot of serum was used immediately for determination of serum total and high-density lipoprotein cholesterol levels.40,41 Whole-blood glycosylated hemoglobin was determined using affinity chromatography (Isolab Inc, Akron, Ohio) from nonfasting blood samples. Smoking and diabetes history were obtained as part of a medical questionnaire. Participants were asked to bring to the examination all medications (prescription and over-the-counter) that they were currently taking. The examiner listed all the medications that were brought to the examination and asked if the participant was taking any others. When medications were not brought to the examination, a follow-up telephone call was made to obtain the missing information. Use of medications as risk factors for eye disease was not a primary aim of our study and we did not collect information on dose or duration of use. Statins included medications in which the active ingredient was a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and that were being used on a regular basis by those who reported taking them. Other reported lipid-lowering preparations were primarily niacin, gemfibrozil, and cholestyramine.

Analyses included all persons with gradable photographs for both eyes at both the third and fourth examinations. Logistic regression was used to examine the incidence of cataract with regard to statin use adjusting for age and other confounders. Models were derived based on our hypotheses.

---

**Figure 1.** Beaver Dam Eye Study: Overall Participant Flow

![Flowchart showing participant flow through the Beaver Dam Eye Study](chart.png)

*The 598 nonparticipants at the first 2 examinations include 20 who completed interviews at both examinations.*
RESULTS

Among the 2962 persons participating in the third examination, 1340 were free of all types of cataract and were at risk of incidence of any type of cataract. Photographs were available for both eyes at the fourth examination for 1048 of these eligible individuals. Two hundred fourteen persons were using statins at the third examination. Incidence of any cataract was not significantly lower among the statin users after adjusting for age (Table 1). If the 19 persons free of cataract at the third examination who had cataract surgery by the fourth examination are included in the analysis as having developed incident cataract, the age-adjusted odds ratio (OR) is 0.74 (95% confidence interval [CI], 0.50-1.09).

Each specific type of cataract has been found to be associated with different risk factors except age. Therefore, each cataract type was examined separately (Table 1). Among those at risk of incidence of a given cataract type, 210 developed nuclear cataract, 100 developed cortical cataract, and 50 developed posterior subcapsular cataract (not mutually exclusive). The respective ORs, adjusted for age, for incident nuclear, cortical, and posterior subcapsular cataracts 5 years after the third examination in statin users were 0.55 (95% CI, 0.36-0.84; P = .006), 1.28 (95% CI, 0.79-2.08; P = .31), and 0.82 (95% CI, 0.39-1.71; P = .59) (Table 1). The small number of cases of cortical and posterior subcapsular cataracts limited our ability to conduct further analyses, but we reanalyzed nuclear cataract to adjust for other possible confounders (factors shown in Table 2). Those developing nuclear cataract were more likely to be older, to be female, to have had less education, and to have lower income than those free of incident cataract. TABLE 3 shows analyses adjusting for all significant and biologic rationale. Because of the limited sample size, we did not assess interactions and we limited confounders for adjustment. The SAS software program was used for all analyses.

### Table 1. Distribution and Age-Adjusted ORs for Each Cataract Type Based on Statin Use

<table>
<thead>
<tr>
<th>Cataract Type</th>
<th>No. in Each Group*</th>
<th>Incidence, No. (%)</th>
<th>Age-Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any cataract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No statin use</td>
<td>834</td>
<td>185 (22.2)</td>
<td>1.00</td>
</tr>
<tr>
<td>Statin use</td>
<td>214</td>
<td>42 (19.6)</td>
<td>0.74 (0.50-1.10)</td>
</tr>
<tr>
<td>Nuclear cataract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No statin use</td>
<td>1029</td>
<td>177 (17.2)</td>
<td>1.00</td>
</tr>
<tr>
<td>Statin use</td>
<td>270</td>
<td>33 (12.2)</td>
<td>0.56 (0.36-0.84)</td>
</tr>
<tr>
<td>Cortical cataract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No statin use</td>
<td>1006</td>
<td>75 (7.5)</td>
<td>1.00</td>
</tr>
<tr>
<td>Statin use</td>
<td>253</td>
<td>25 (9.9)</td>
<td>1.28 (0.79-2.08)</td>
</tr>
<tr>
<td>Posterior subcapsular cataract</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No statin use</td>
<td>1209</td>
<td>41 (3.4)</td>
<td>1.00</td>
</tr>
<tr>
<td>Statin use</td>
<td>304</td>
<td>9 (3.0)</td>
<td>0.82 (0.39-1.71)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; OR, odds ratio.

*Numbers are those in each exposure category at risk of the outcome (ie, without prevalent specific type of cataract).
cant confounders; education, income, lipid levels, and hypertension did not alter the models. Although smoking and diabetes were not strongly related, because of the possibility that these characteristics might confound analyses with statins, we recalculated the models limiting the analyses to those who had never smoked and did not have diabetes. The relationship persisted, with an OR of 0.37 (95% CI, 0.16-0.82; P = .01).

Because we did not collect information on total duration of statin use, we evaluated current use at the second and fourth examinations in addition to use at the third examination in association with incident nuclear cataract at the fourth examination. Most people continued to take statins once they began. The OR for incident nuclear cataract among the 45 individuals who used statins at 3 consecutive examinations was 0.29 (95% CI, 0.09-0.96), while the OR for those taking statins at 2 visits was 0.61 (95% CI, 0.38-0.98), and the OR for those starting statins between the third and fourth visit was 0.98 (95% CI, 0.66-1.46) (Table 4). Because of the small sample sizes, we were able to adjust only for age in this analysis.

Simvastatin (n=95) and atorvastatin (n=98) were the most commonly used statin preparations at the third examination, followed by pravastatin (n=36), fluvasitatin (n=35), and lovastatin (n=6). We recalculated analyses (controlling only for age) of incidence of nuclear cataract by statin type. Six percent of the simvastatin users developed nuclear cataract, while 16% of the atorvastatin users and 14% of users of all other statins (combined pravastatin, fluvasitatin, and lovastatin) developed nuclear cataract. Compared with nonusers, the age-adjusted ORs were 0.28 (95% CI, 0.12-0.65) for simvastatin, 0.73 (95% CI, 0.41-1.33) for atorvastatin, and 0.67 (95% CI, 0.34-1.33) for all other statins.

Finally, a total of 76 individuals at risk of incident nuclear cataract had cataract surgery between the third and fourth examinations, of whom 51 had

Table 2. Characteristics at the Third Examination (1998-2000) of Participants Who Developed Nuclear Cataract Compared With Those Who Did Not

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (N = 1299)</th>
<th>Incident Nuclear Cataract (n = 210)</th>
<th>No Incident Nuclear Cataract (n = 1089)</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SE), y</td>
<td>63.2 (0.2)</td>
<td>68.1 (0.5)</td>
<td>62.3 (0.2)</td>
<td>.008</td>
</tr>
<tr>
<td>Female</td>
<td>697 (53.7)</td>
<td>130 (61.9)</td>
<td>567 (52.1)</td>
<td>.006</td>
</tr>
<tr>
<td>Education, mean (SE), y</td>
<td>13.1 (0.1)</td>
<td>12.5 (0.2)</td>
<td>13.3 (0.1)</td>
<td>.02</td>
</tr>
<tr>
<td>Annual income, $§</td>
<td>Unknown 72 (5.5)</td>
<td>15 (7.1)</td>
<td>57 (5.2)</td>
<td>.002</td>
</tr>
</tbody>
</table>
<10 000 | 36 (2.8) | 12 (5.7) | 24 (2.2) |
10 000-19 000 | 138 (10.6) | 40 (19.0) | 98 (9.0) |
20 000-29 000 | 223 (17.2) | 46 (21.9) | 177 (16.3) |
30 000-44 000 | 288 (22.2) | 42 (20.0) | 246 (22.6) |
>44 000 | 542 (41.7) | 55 (26.2) | 487 (44.7) |
| Body mass index, mean (SE)§ | 30.4 (0.2) | 30.0 (0.4) | 30.5 (0.2) | .59 |
| Blood pressure, mean (SE), mm Hg§ | | | | |
| Systolic | 129.2 (0.5) | 132.1 (1.3) | 128.6 (0.5) | .19 |
| Diastolic | 76.0 (0.3) | 74.5 (0.7) | 76.3 (0.3) | .99 |
| High blood pressure (>140/90 mm Hg)§ | Unknown 0 | 0 | 0 | .47 |
| Yes | 663 (51.0) | 86 (41.0) | 550 (50.5) |
| History of cardiovascular disease§ | Unknown 1 (0.1) | 0 | 1 (0.1) | .16 |
| No | 1164 (90.6) | 188 (89.5) | 976 (89.6) |
| Yes | 134 (10.3) | 22 (10.5) | 112 (10.3) |
| Diabetes§ | Unknown 12 (0.9) | 2 (1.0) | 10 (0.9) | .65 |
| No | 1153 (88.8) | 186 (88.6) | 967 (88.8) |
| Possible | 19 (1.5) | 2 (1.0) | 17 (1.6) |
| Definite | 115 (8.9) | 20 (9.5) | 95 (8.7) |
| History of smoking§ | Unknown 0 | 0 | 0 | .08 |
| Never | 614 (47.3) | 100 (47.6) | 514 (47.2) |
| Past | 546 (42.0) | 84 (40.0) | 462 (42.4) |
| Current | 139 (10.7) | 26 (12.4) | 113 (10.4) |

*Data are expressed as No. (%) unless otherwise noted.
†All P values are for incident vs no incident nuclear cataract, adjusted for age (except for age comparison); data classified as unknown were not included in P value calculations.
‡Calculated as weight in kilograms divided by height in meters squared.
§At third examination.

Table 3. Five-Year Incidence of Nuclear Cataract Identified at Fourth Examination, Classified by Use of Statins at Third Examination, 1998-2000

<table>
<thead>
<tr>
<th>Incidence of nuclear cataract, No. (%)</th>
<th>No Statin Use (N = 1029)</th>
<th>Statin Use (N = 270)</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>1029 (17.2)</td>
<td>270 (12.2)</td>
<td></td>
</tr>
<tr>
<td>Never Smokers With No Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>1.00</td>
<td>0.55 (0.36-0.84)</td>
<td>1.00</td>
</tr>
<tr>
<td>Adjusted*</td>
<td>1.00</td>
<td>0.60 (0.39-0.92)</td>
<td>1.00</td>
</tr>
<tr>
<td>Fully adjusted†</td>
<td>1.00</td>
<td>0.60 (0.39-0.93)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; OR, odds ratio.
*Adjusted for age, sex, total cholesterol, and high-density lipoprotein cholesterol.
†Fully adjusted for age, sex, total cholesterol, high-density lipoprotein cholesterol, smoking, and diabetes.
cortical or posterior subcapsular cataract, 4 had missing information, and 21 were free from all types of cataract. Including these patients with possible incident nuclear cataract in the analyses as having incident nuclear cataract did not change the results.

COMMENT

These data demonstrate an inverse association between use of statins and incidence of nuclear cataract but not incidence of cortical or posterior subcapsular cataracts. Different relationships of specific exposures to specific cataract types have been previously observed. For example, nuclear cataract is associated with cigarette smoking, 23,43,44 cortical cataract with UV exposure, 26 and posterior subcapsular cataract with hypertension 27 and use of steroid preparations. 35,46 There is also evidence of different genetic patterns associated with different types of cataract. 57-59 Thus, it is plausible that protective factors may differ. As previously noted, a protective effect of statins on nuclear cataract is biologically plausible because oxidative stress, presumably the mechanism behind the association of smoking and nuclear cataract. Although other studies 57-61 did not report a protective effect of statins for nuclear cataract, a relationship is still plausible. 58-61 Most of the other studies in humans did not objectively record the degree of nuclear sclerosis (or other cataract type); investigators usually relied on clinical examinations, which are difficult to standardize between examiners even at the same clinical centers, let alone in multicenter studies. Also, in some studies it is not clear that the assessment was unbiased with regard to treatment. That, coupled with the anticipation of a deleterious effect on the lens, suggests that the lack of a previous protective finding does not mean that one does not exist.

Because smoking has been found in many studies (including ours) to increase the risk of nuclear cataract 17,25,43 and diabetes less consistently so 44,62-65 we evaluated the association of statins in nonsmokers without diabetes. There was no meaningful difference in this association compared with the estimates derived from the entire population. This suggests that statins may act on physiologic mechanisms that are not influenced by smoking or diabetes. Our small sample sizes limited our ability to further adjust for other potential risk factors. In another analysis, we controlled for level of serum total cholesterol in the event that the statin effect might reflect a beneficial effect on that lipid. This had no effect either when compared with the entire population or when restricting the analysis to those who were nonsmokers and did not have diabetes. These adjustments did not materially affect the estimate of the relationship of statins to nuclear cataract, suggesting that the mechanism is not entirely (or at all) due to decreased serum total cholesterol. Additional models adjusting for other potential confounders such as education, income, and hypertension did not affect the results. Nevertheless, our results could be affected by uncontrolled confounding.

Cataract surgery may be performed for any number of reasons that may be unrelated or only partly related to the presence of nuclear cataract as we have defined it. Cataract surgery criteria differ between practices, and more minimal levels of nuclear opacity may be considered a surgical indication in some practices. Also, persons with cortical or posterior subcapsular cataracts with minimal or no nuclear opacity may have had surgery. In addition, surgery may have been performed because of vision complaints that actually arose from previously undiagnosed or underappreciated conditions unrelated to nuclear cataract. For these reasons, our emphasis is placed on using gradings from photographs for the specific cataract types.

In examining whether a specific type of statin has differential effects, we found that simvastatin users had significantly less nuclear cataract development compared with nonusers of statins. The smaller reductions among atorvastatin and other statin users were not significant, but we did not have adequate power to identify significant relationships for ORs between 0.5 and 0.9. It is possible that duration of use may have been somewhat greater in users of simvastatin than for atorvastatin or other statins and dose may have had an effect. Although drug exposure was an inter-

---

Table 4. Incident Nuclear Cataract by Duration of Statin Use

<table>
<thead>
<tr>
<th>Statin Exposure</th>
<th>No of Participants</th>
<th>Incidence, No. (%)</th>
<th>Age-Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No statin exposure</td>
<td>779</td>
<td>133 (17.1)</td>
<td>1.00</td>
</tr>
<tr>
<td>Statin use started between third and fourth examinations</td>
<td>250</td>
<td>44 (17.6)</td>
<td>0.98 (0.66-1.46)</td>
</tr>
<tr>
<td>Statin use during third examination only, then stopped</td>
<td>26</td>
<td>3 (11.5)</td>
<td>0.51 (0.14-1.79)</td>
</tr>
<tr>
<td>Statin use during third and fourth examinations</td>
<td>196</td>
<td>26 (13.3)</td>
<td>0.61 (0.38-0.98)</td>
</tr>
<tr>
<td>Statin use during second and third examinations, then stopped</td>
<td>3</td>
<td>1 (33.3)</td>
<td>1.26 (0.09-17.23)</td>
</tr>
<tr>
<td>Statin use during second, third, and fourth examinations</td>
<td>45</td>
<td>3 (6.7)</td>
<td>0.29 (0.09-0.96)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; OR, odds ratio.
est when the study was developed, it was not a primary aim. For pragmatic reasons, we opted not to obtain dose and duration information for many hundreds of drugs that were being assessed. Although information on dose and duration were not available, we were able to categorize statin users at each examination and consider the number of consecutive examinations with statin use as a surrogate for generally longer vs shorter duration of use. Those taking statins for more consecutive examinations had a lower rate of developing nuclear cataract despite overlapping CIs, which is compatible with the possibility that duration may be important.

Despite the small sample size, which limited the factors we could control for, we observed an association between statin use—in particular, simvastatin—and incident nuclear cataract. We did not find such a relationship for cortical or posterior subcapsular cataracts. Further study of the relationship of cataract and statin use is needed in which each type of cataract is considered individually. Further follow-up of our cohort, with anticipated increase in number of persons with cataract and wider use of statins, will permit us to evaluate whether our finding persists. In addition, evaluating the lens for the possibility of nuclear cataract could be incorporated into clinical trials that are currently ongoing or planned for purposes of evaluating these drugs in systemic diseases. This would provide important information concerning the association we have observed. The potential health care implications of the relationship between statin use and cataract incidence are great because nuclear cataract is the most common type of age-related cataract.

Author Contributions: Dr B. Klein had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: B. Klein, Lee. Acquisition of data: R. Klein, Lee. Analysis and interpretation of data: R. Klein, Lee, Grady. Drafting of the manuscript: B. Klein, Lee. Critical revision of the manuscript for important intellectual content: R. Klein, Lee, Grady. Statistical analysis: Lee.

Obtained funding: B. Klein, R. Klein.
Administrative, technical, or material support: B. Klein, Grady.
Study supervision: B. Klein.

Financial Disclosures: None reported.

Supporting Information: The National Eye Institute grant EY06594 provided funding for the entire study; Research to Prevent Blindness, New York, NY, provided further additional support for data analyses.

Role of the Sponsor: The study funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

REFERENCES

STATIN USE AND INCIDENT NUCLEAR CATARACT

42. SAS Institute Inc.


 Volunteer Your Services
Physicians and other health professionals can view a listing of international volunteer opportunities available at http://jamaicareer.net.ama-assn.org/misc/volunteer.dtl. Broaden your experience while learning more about the world—and yourself. Reap unexpected rewards by helping others.